Roche to Acquire PathAI for $1.05 Billion to Bolster Digital Pathology Capabilities

May 7, Basel,Roche Announces $1.05 Billion (Approx. 7.143 Billion RMB) Final Agreement to Acquire PathAI——A U.S.-based company providing digital pathology and artificial intelligence technology for pathology laboratories and the biopharmaceutical industry.

This acquisition builds on the successful partnership between Roche and PathAI, established in 2021 and expanded in 2024, which includes the development of AI-supported companion diagnostic algorithms.

Upon completion of the transaction in the second half of the year, the acquired entity will become part of Roche Diagnostics. Under the terms of the agreement, Roche will pay an upfront payment of $750 million and up to $300 million in additional milestone payments.

This acquisition strengthens Roche's position in the field of digital pathology, which is transforming a wide range of manual workflows into fully automated, AI-driven processes and insights. Digital pathology enables the creation of high-resolution digital images from physical tissue on slides, allowing pathologists to utilize AI tools to facilitate diagnostic workflows and deliver faster results for patients.

Roche Diagnostics CEO Matt Sause stated:"Digital pathology has the potential to improve the precise diagnosis of cancer and enable doctors to provide better customized treatment plans. Integrating PathAI into Roche Diagnostics will allow us to combine its first-class digital pathology tools with our leading oncology diagnostics platform, providing doctors with better insights and delivering improved outcomes for patients worldwide."

PathAI CEO and co-founder Andy Beck said:"The collaboration with Roche marks a new era for PathAI, enabling us to fulfill our mission of improving patient outcomes through AI-powered pathology at an unprecedented scale and speed. Roche's global infrastructure and expertise will bring our digital diagnostic technologies to patients worldwide."

PathAI's AISight IMS Software Interface is Efficient and User-Friendly, Seamlessly Integrating Advanced Analytics and Workflow Functions in Digital Pathology Laboratories. In the Rapidly Growing Pathology Market, Roche Intends to Promote This Solution Globally.

Moreover, the expanded capabilities enhance Roche's competitiveness in the precision medicine field by strengthening its biopharmaceutical services.PathAI's strengths in AI-driven solutions, including clinical trial support and translational research, will complement Roche's deep expertise in companion diagnostics.The combination of these capabilities will facilitate the discovery of new biomarkers, potential drug targets, and novel diagnostic tools, increasing the value Roche brings to biopharmaceutical companies.